We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App




Human Papilloma Virus Tests Compared and Evaluated

By LabMedica International staff writers
Posted on 29 Nov 2016
High-risk human papillomavirus testing is already part of cervical cancer screening programs in a number of countries and new tests need to be validated not only in clinical studies but also in routine screening settings with regard to their clinical performance.

As persistent infection with High-Risk Human Papillomaviruses (HR HPV) is a necessary risk factor for the development of (pre)-cancer, numerous HPV tests are nowadays commercially available to be used in cervical cancer screening programs. More...
However, only a small number of these tests have been approved by the authorities.

Scientists at the University Hospital Tübingen (Germany) and their colleagues evaluated in a random sample of 1,456 patients from a German routine screening population of 13,372 women equal to or older than 30 years of age screened primarily by liquid-based cytology (LBC) that was complemented by 48 CIN3+ cases. Clinical sensitivities, relative specificities and positive predictive values (PPV) for both HPV tests were determined based on histologically confirmed high-grade cervical disease (CIN3+) as clinical outcome.

LBC was performed by the ThinPrep 2000 Processor (Hologic, Bedford, MA, USA) and cytology results were reported using the Munich Nomenclature II and were translated into The Bethesda System (TBS) LBC results were considered negative when the result was Pap I/II (Normal) or Pap IIw (ASC-US); all other results were considered positive. LBC samples were tested by Abbott RealTime High Risk HPV Test (RT hrHPV, Abbott Laboratories, Abbott Park, IL, USA). HPV genotyping was carried out using the INNO-LiPA HPV Genotyping Extra test (Fujirebio, Ghent, Belgium), which identifies 20 HPV genotypes.

The investigators found that HR HPV prevalence in residual LBC samples was found to be 5.4% by the RT hrHPV test and 5.6 % by the HR HC2 test, respectively. There was a high overall agreement between the RT hrHPV test and the HC2 assay for detection of HR HPV. Relative sensitivities for detection of CIN3+ in patients with abnormal cytology was 93.8 % for the RT hrHPV assay and 97.9 % for HC2. Relative specificities and PPVs were comparable for both tests. The highest PPV was calculated for the specific detection of HPV16 by the RT hrHPV test (84.2 %). The RT hrHPV test showed a reduced sensitivity for detection of HVP31-positive CIN3 +.

The authors concluded that that the sensitivities and relative specificities of the RT hrHPV and the HR HC2 test are comparable. However, it appears that the RT hrHPV test has a reduced sensitivity for the detection of HPV type 31, which in this study has led to two CIN3+ cases missed by the RT hrHPV test. A considerable benefit of the RT hrHPV HPV test is its separate type specific detection of the most prevalent HPV genotypes 16 and 18, which together account for a total of an estimated 70.4 % of cervical cancer cases worldwide. The study was published on November 11, 2016, in the journal BMC Infectious Diseases.

Related Links:
University Hospital Tübingen
Hologic
Abbott Laboratories
Fujirebio

New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
Verification Panels for Assay Development & QC
Seroconversion Panels
New
STI Test
REALQUALITY RQ-SevenSTI
New
Mumps Test
ReQuest MUMPS IgM Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.